I am not sure I even read that correctly. I have to tell you, if I read your response right, that is a grossly inaccurate take on how scientific research works or at least is supposed to work (to put it mildly). The agency that funds your scientific research (whether it is government sponsored research or research supported by a foundation of some sort) does not get to dictate your results That is scientific fraud. Nothing to do with double edged swords etc.-if you are telling a scientist to produce results that you want to see and disregarding their actual results, that is scientific fraud.
When the government pressures scientists to do this, they are engaging in highly unethical behavior. Environmental scientists working on risk assessment of different chemicals for instance, are not supposed to make up stuff that the government wants to hear. And nobody should be ok with the government interfering with science.
For instance, I am a researcher and my work is funded by the NIH-this does not mean that the NIH gets to tell me what my results should be. Our lab note-books for instance are considered federal documents. I am not sure scientific fraud is still considered a federal offense, but it used to be (when the research support comes from federal agencies such as the NIH and NSF). And there have been scientists who have gone on trial for the same:
http://en.wikipedia.org/wiki/Thereza_Imanishi-KariAnd it is just as fraudulent for an external agency to pressure a scientist to misrepresent their results, as it is for a rogue scientist to invent their own results a la Jan Schon.
These are not issues to have a lax attitude towards. It absolutely is scientific fraud, whether it is this disgusting administration pressuring a government agency to support laxer air quality standards, or for instance a pharmaceutical giant suppressing data that might hurt their profits. And when science is suppressed for profits for instance, this sort of stuff results:
http://www.hindu.com/seta/2008/04/24/stories/2008042450061500.htmVioxx safety data manipulated
R. PRASAD
A Merck’s internal communication talks of the drug being associated with an increased risk of causing deaths
snip from the article:
Vioxx went on to become a blockbuster drug in the five years that it was in the market.
New evidence published in the reputed Journal of the American Medical Association (JAMA) confirms that the company was well aware of its dangers even before it withdrew the drug in 2004. The paper looked at human clinical trials done for Alzheimer’s starting 1999.
It may well turn out to be one of the greatest drug scandals in the recent past. And it once again confirms that many pharmaceutical companies will stoop to any level and act in an unscrupulous manner to get a blockbuster into the market. Never mind that volunteers and patients are put to great risks.
“Where patients come first,” ironically, is the drug maker’s slogan!
Merck, like many other drug companies, has been found to have suppressed and manipulated certain critical data that misled the regulatory body — the U.S. Food and Drug Administration (FDA).
The confidential information provided by Merck to the FDA and internal analyses conducted by the company reveal how systematically it went about the process.
The clinical trials for Alzheimer’s were quite different from other trials. Apart from looking at the safety issue during the course of the trial (on-treatment safety), the trials looked for safety even after the completion of the trial duration (intention-to-treat). At least, that is how the company projected it.
Results published in journals had stated that the drug was “well-tolerated” and safety was not an issue. But any data on deaths that may have occurred 14 days after the completion of the trials were not included.
The authors found that even the Safety Update Report (SUR) filed in 2001 by Merck to the FDA did not explain how it arrived at the number of deaths seen during the trials. It did not include deaths, if any, that had occurred after the 14-day period.
Suppressing data
“In other words, it appears that the sponsor presented only an on-treatment and not an intention-to-treat analysis for total mortality,” the authors noted. This was a clear case of Merck withholding crucial safety data from the FDA.
The proof of misleading and withholding critical safety data from the FDA came in the form of an internal memorandum sent by Merck’s statistician few months before it submitted the Safety Update Report to the regulator in 2001.